Related references
Note: Only part of the references are listed.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Bcr-abl-independent imatinib-resistant k562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors
Sang Min Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells
Dong-Sik Ju et al.
CANCER LETTERS (2007)
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)
Nikolas von Bubnoff et al.
BLOOD (2006)
TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential
G Fiorucci et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity
M Okada et al.
BLOOD (2004)
Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
SW Cowan-Jacob et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
NJ Donato et al.
CANCER RESEARCH (2004)
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Y Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
V Nardi et al.
CURRENT OPINION IN HEMATOLOGY (2004)
Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis
XS Hao et al.
APOPTOSIS (2003)
TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells
K Uno et al.
BLOOD (2003)
Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP
V Hietakangas et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571
R Nimmanapalli et al.
ONCOGENE (2002)
FLICE-inhibitory proteins: Regulators of death receptor-mediated apoptosis
A Krueger et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL
M Horita et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)